Polaris Capital Management, LLC — Global Equity Composite on Cytokinetics, Incorporated
Thesis
Polaris added Cytokinetics following FDA approval of Myqorzo for hypertrophic cardiomyopathy. The fund believes Myqorzo compares favorably with Bristol Myers Squibb's Camzyos because it offers better symptom relief with simpler dosing. The approval therefore creates a commercial opportunity around a differentiated treatment in an established disease category.
“We added Cytokinetics to our portfolio, a U.S. biopharma company with FDA approval for Myqorzo for hypertrophic cardiomyopathy.”